Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 82c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $61.65 +3.56%
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.39), $0.82 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $62.5 million versus the consensus estimate of $172.97 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Chime Financial, Inc. (CHYM) Tops Q3 EPS by 13c ; Offers Guidance
- Ingevity (NGVT) Tops Q3 EPS by 7c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
